{"id":61482,"date":"2025-06-25T07:04:05","date_gmt":"2025-06-25T05:04:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\/"},"modified":"2025-06-25T07:04:05","modified_gmt":"2025-06-25T05:04:05","slug":"galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\/","title":{"rendered":"Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nSystemic Sclerosis (SSc) is a life-threatening autoimmune disease that causes severe inflammation and fibrosis, while Chronic Pruritus of Unknown Origin (CPUO) is characterized by a persistent, chronic itch with an unknown cause<sup>1-3<\/sup><\/li>\n<li>\nNemolizumab is the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31. It is approved for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world<sup>4-6<\/sup><\/li>\n<li>\nIL-31 is a neuroimmune cytokine that is involved in inflammation and fibrosis \u2013 both hallmarks of SSc \u2013 and drives itch, a key symptom of CPUO<sup>1,3,4<\/sup><\/li>\n<li>\nEnrollment for Galderma\u2019s phase II studies of nemolizumab is planned to begin in H2 2025<\/li>\n<\/ul>\n<p>ZUG, Switzerland&#8211;(BUSINESS WIRE)&#8211;Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO) \u2013 two chronic conditions with high unmet need.<sup>1-3,7<\/sup><\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20250624095800\/en\/2506646\/5\/GALDERMA_LOGO_BLACK_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250624095800\/en\/2506646\/22\/GALDERMA_LOGO_BLACK_RGB.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20250624095800\/en\/2506646\/5\/GALDERMA_LOGO_BLACK_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250624095800\/en\/2506646\/21\/GALDERMA_LOGO_BLACK_RGB.jpg\"><\/a><\/p>\n<p>\nNemolizumab is a monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31, a neuroimmune cytokine that plays a role in driving itch \u2013 the main symptom of CPUO \u2013 and inflammation and fibrosis, which are hallmarks of SSc.<sup>1,3,4<\/sup><\/p>\n<table cellspacing=\"0\" class=\"bwblockalignl bwtablemarginb bwwidth100\">\n<tr>\n<td class=\"bwrowaltcolor0 bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwwidth96\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u201cInvestigating nemolizumab in two new trials in Systemic Sclerosis and Chronic Pruritus of Unknown Origin, both of which are associated with poor patient outcomes and low quality of life, underscores our commitment to addressing skin conditions with high unmet needs. These trials may help us better understand these complex diseases and offer hope for patients seeking relief from these severe and potentially life-threatening conditions.\u201d<\/p>\n<p><b>BALDO SCASSELLATI SFORZOLINI, M.D., PH.D.<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>GLOBAL HEAD OF R&amp;D<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>GALDERMA<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Systemic Sclerosis (SSc)<\/b><\/p>\n<p>\nSSc is a rare, potentially fatal autoimmune disease that causes inflammation and fibrosis (hardening) of the skin and internal organs.<sup>1<\/sup> It most commonly affects women between the ages of 30 and 50 years old, often leading to a lower quality of life and a much higher risk of death compared to healthy people of the same age.<sup>2,8<\/sup> Currently, there are no approved therapies that address the disease as a whole, highlighting the urgent need for effective treatments.<sup>1,2,8<\/sup><\/p>\n<p>\nGalderma\u2019s phase II proof-of-concept study is a multicenter, randomized, double-blind, placebo-controlled study investigating the pharmacokinetics and pharmacodynamics of nemolizumab in adults with SSc. Patient enrollment is planned to begin in H2 2025, with completion anticipated in 2028. This trial represents a significant step towards addressing the remaining unmet treatment needs in SSc and demonstrates Galderma\u2019s commitment to driving progress for patients living with this disease.<\/p>\n<p>\nThe study was designed in collaboration with a Steering Committee of world-leading rheumatology and dermatology experts, including lead trial investigator, Professor Oliver Distler, M.D., Z\u00fcrich, Switzerland; Professor Dinesh Khanna, M.D., Director of the Scleroderma Program, University of Michigan, United States (U.S.); Professor Robert Spiera, M.D., Director of the Scleroderma, Vasculitis and Myositis Center, Hospital for Special Surgery, New York, U.S.; and Professor Johann Gudjonsson, M.D., PhD, Dermatologist, University Hospital Michigan, U.S.<\/p>\n<p>\nThe trial is expected to be conducted in several countries in North America, Europe and South America. More information about the study will be made available soon on the clinicaltrials.gov website.<\/p>\n<table cellspacing=\"0\" class=\"bwblockalignl bwtablemarginb bwwidth100\">\n<tr>\n<td class=\"bwrowaltcolor0 bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwwidth96\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n\u201cSystemic Sclerosis can have a profound impact on both the quality and length of a person\u2019s life. It causes the skin to harden, damages blood vessels, leads to joint pain, and can result in serious fibrosis in multiple internal organs, sometimes with life-threatening consequences. With no currently approved treatments that are indicated to treat the several symptoms this autoimmune disease presents, I look forward to investigating the role that nemolizumab could potentially play in this condition.\u201d<\/p>\n<p><b>PROFESSOR OLIVER DISTLER, M.D.<\/b><br \/><b>LEAD INVESTIGATOR: SYSTEMIC SCLEROSIS PHASE II STUDY<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>Z\u00dcRICH, SWITZERLAND<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Chronic Pruritus of Unknown Origin (CPUO)<\/b><\/p>\n<p>\nCPUO is an underdiagnosed condition defined as itch lasting for more than six weeks without an identified cause and mostly affects the elderly.<sup>3<\/sup> The chronic and persistent itch is often described as being as debilitating as chronic pain, leading to reduced quality of life and affecting sleep patterns and mood.<sup>3,7<\/sup> There are currently no approved treatments for this condition.<sup>3<\/sup><\/p>\n<p>\nGalderma\u2019s new phase II CPUO trial reinforces the company\u2019s commitment to exploring options for patients with chronic skin conditions that significantly impact quality of life. This randomized, double-blind, placebo-controlled proof-of-concept study will explore the pharmacokinetics and pharmacodynamics of nemolizumab in adults. Enrollment is expected to start in H2 2025 in the U.S., with completion anticipated in 2026. The study was designed in collaboration with a Steering Committee of world-leading dermatology experts, including the lead investigator Dr. Shawn Kwatra, M.D., PhD., Joseph W. Burnett Endowed Professor, Chairman of Dermatology, University of Maryland School of Medicine, U.S., and Dr. Sarina Elmariah, MD, PhD, MPH, Associate Professor and Dermatology Director at the Center for Itch and Neurosensory Disorders at the University of California in San Francisco, U.S.<\/p>\n<p>\nThe study is being conducted in the U.S. and more information about the study will be made available soon on the clinicaltrials.gov website.<\/p>\n<table cellspacing=\"0\" class=\"bwblockalignl bwtablemarginb bwwidth100\">\n<tr>\n<td class=\"bwrowaltcolor0 bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwwidth96\" colspan=\"1\" rowspan=\"1\" style=\"height:69px;\">\n<p class=\"bwcellpmargin bwalignc\">\n\u201cIt is challenging to treat Chronic Pruritus of Unknown Origin as physicians have limited therapeutic options specifically targeting the underlying cause of itch. With the extensive data showing that IL-31 is a key driver of itch, I\u2019m excited to explore whether nemolizumab\u2019s inhibition of IL-31 signaling might effectively reduce the intractable itch experienced by patients with Chronic Pruritus of Unknown Origin.\u201d<\/p>\n<p><b>DOCTOR SHAWN KWATRA, M.D., PHD<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>LEAD INVESTIGATOR, CHRONIC PRURITUS OF UNKNOWN ORIGIN PHASE II STUDY<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>JOSEPH W. BURNETT ENDOWED PROFESSOR<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>CHAIRMAN OF DERMATOLOGY, UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE, U.S.<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0 bwwidth2\" colspan=\"1\" rowspan=\"1\" style=\"height:69px;\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>About nemolizumab<\/b><\/p>\n<p>\nNemolizumab was approved in August 2024 by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of adults with prurigo nodularis.<sup>5<\/sup> In December 2024, it was also approved by the U.S. FDA for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and\/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.<sup>5<\/sup> To date, nemolizumab is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including in the European Union, Australia, Singapore, Switzerland and the United Kingdom. Additional regulatory submissions and reviews are ongoing.<\/p>\n<p>\nNemolizumab was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga<sup>\u00ae<\/sup> and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients.<sup>9,10<\/sup><\/p>\n<p>\n<b>About Galderma<\/b><\/p>\n<p>\nGalderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body\u2019s largest organ \u2013 the skin \u2013 meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.galderma.com&amp;esheet=54281751&amp;newsitemid=20250624095800&amp;lan=en-US&amp;anchor=www.galderma.com&amp;index=1&amp;md5=c32799f4ddc13a948743d0c4e76e5790\" rel=\"nofollow\" shape=\"rect\">www.galderma.com<\/a>.<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignm bwpadl0 bwwidth2\" colspan=\"2\" rowspan=\"1\"><b>References<\/b><\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth2 bwvertalignt bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1.<\/p>\n<\/td>\n<td class=\"bwvertalignb bwwidth98 bwpadl3\" colspan=\"1\" rowspan=\"1\">Jimenez SA, Mendoza FA, Piera-Velasquez S. A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways. <i>Front Immunol<\/i>. 2025;16: 1551911. doi: 10.3389\/fimmu.2025.1551911<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth2 bwvertalignt bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2.<\/p>\n<\/td>\n<td class=\"bwvertalignb bwwidth98 bwpadl3\" colspan=\"1\" rowspan=\"1\">Truchetet ME, et al. Current Concepts on the Pathogenesis of Systemic Sclerosis. <i>Clin Rev Allergy Immunol<\/i>. 2021;64(3): 262\u2013283. doi: 10.1007\/s12016-021-08889-8<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth2 bwvertalignt bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3.<\/p>\n<\/td>\n<td class=\"bwvertalignb bwwidth98 bwpadl3\" colspan=\"1\" rowspan=\"1\">Teresa J, et al. Therapeutics in chronic pruritus of unknown origin. <i>Itch<\/i>. 2023;8(1): pe64. doi: 10.1097\/itx.0000000000000064<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth2 bwvertalignt bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n4.<\/p>\n<\/td>\n<td class=\"bwvertalignb bwwidth98 bwpadl3\" colspan=\"1\" rowspan=\"1\">Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. <i>J Allergy Clin Immunol<\/i>. 2020;145(1): 173-182. doi: 10.1016\/j.jaci.2019.08.013<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth2 bwvertalignt bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n5.<\/p>\n<\/td>\n<td class=\"bwvertalignb bwwidth98 bwpadl3\" colspan=\"1\" rowspan=\"1\">Nemluvio<sup>\u00ae<\/sup> U.S. Prescribing Information. Available <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.galderma.com%2Fsites%2Fdefault%2Ffiles%2F2024-12%2FNemluvio_Dual%2520PI%2520for%2520website%252013Dec24.pdf&amp;esheet=54281751&amp;newsitemid=20250624095800&amp;lan=en-US&amp;anchor=online&amp;index=2&amp;md5=dbf229c77bc71890e6404146a473ff27\" rel=\"nofollow\" shape=\"rect\">online<\/a>. Accessed June 2025<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth2 bwvertalignt bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n6.<\/p>\n<\/td>\n<td class=\"bwvertalignb bwwidth98 bwpadl3\" colspan=\"1\" rowspan=\"1\">Nemluvio<sup>\u00ae<\/sup> European Medicines Agency. Summary of Product Characteristics. Available <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fdocuments%2Fproduct-information%2Fnemluvio-epar-product-information_en.pdf&amp;esheet=54281751&amp;newsitemid=20250624095800&amp;lan=en-US&amp;anchor=online&amp;index=3&amp;md5=7b2574e5962e331a8eb5ae7d6f45661b\" rel=\"nofollow\" shape=\"rect\">online<\/a>. Accessed June 2025<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth2 bwvertalignt bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n7.<\/p>\n<\/td>\n<td class=\"bwvertalignb bwwidth98 bwpadl3\" colspan=\"1\" rowspan=\"1\">Andrade E, et al. Interventions for chronic pruritus of unknown origin. <i>CDSR<\/i>. 2020;1(1): CD013128. doi: 10.1002\/14651858.CD013128.pub2<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth2 bwvertalignt bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n8.<\/p>\n<\/td>\n<td class=\"bwvertalignb bwwidth98 bwpadl3\" colspan=\"1\" rowspan=\"1\">Scleroderma &amp; Systemic Sclerosis. National Health Service. Available <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nhs.uk%2Fconditions%2Fscleroderma%2F&amp;esheet=54281751&amp;newsitemid=20250624095800&amp;lan=en-US&amp;anchor=online&amp;index=4&amp;md5=d40991d781a09420cde5dc246b3546f5\" rel=\"nofollow\" shape=\"rect\">online<\/a>. Accessed June 2025<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth2 bwvertalignt bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n9.<\/p>\n<\/td>\n<td class=\"bwvertalignb bwwidth98 bwpadl3\" colspan=\"1\" rowspan=\"1\">Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.chugai-pharm.co.jp%2Fnews%2Fcont_file_dl.php%3Ff%3D220328eMitchga_Maruho_Approval_final.pdf%26src%3D%255b%25250%255d%2C%255b%25251%255d%26rep%3D130%2C908&amp;esheet=54281751&amp;newsitemid=20250624095800&amp;lan=en-US&amp;anchor=online&amp;index=5&amp;md5=38004ca96754838c17ae785d81cf21c0\" rel=\"nofollow\" shape=\"rect\">online<\/a>. Accessed June 2025<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwwidth2 bwvertalignt bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n10.<\/p>\n<\/td>\n<td class=\"bwvertalignb bwwidth98 bwpadl3\" colspan=\"1\" rowspan=\"1\">Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.chugai-pharm.co.jp%2Fnews%2Fcont_file_dl.php%3Ff%3D240326eMitchga_Maruho_Approval.pdf%26src%3D%255b%25250%255d%2C%255b%25251%255d%26rep%3D130%2C1061&amp;esheet=54281751&amp;newsitemid=20250624095800&amp;lan=en-US&amp;anchor=online&amp;index=6&amp;md5=c89c405b413cc3fe73c946011a99d646\" rel=\"nofollow\" shape=\"rect\">online<\/a>. Accessed June 2025<\/td>\n<\/tr>\n<\/table>\n<p>\n\u00a0<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>For further information:<\/p>\n<p><\/b>Christian Marcoux, M.Sc.<br \/>\n<br \/>Chief Communications Officer<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;&#108;&#x74;&#x6f;:&#x63;&#x68;r&#105;&#x73;t&#105;&#x61;n&#46;&#x6d;a&#114;&#x63;o&#117;&#x78;&#x40;&#103;&#x61;&#x6c;&#100;&#x65;&#x72;m&#x61;&#x2e;c&#111;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#99;&#x68;&#114;&#x69;s&#116;&#x69;&#97;&#x6e;&#46;&#x6d;a&#114;&#x63;&#111;&#x75;x&#x40;&#x67;&#97;&#x6c;d&#x65;r&#109;&#x61;&#46;&#x63;o&#x6d;<\/a><br \/>+41 76 315 26 50<\/p>\n<p>Richard Harbinson<br \/>\n<br \/>Corporate Communications Director<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#97;&#x69;&#x6c;&#116;&#111;&#x3a;&#x72;&#105;&#99;&#x68;&#x61;&#114;&#100;&#x2e;&#x68;&#97;&#114;&#x62;&#x69;&#110;&#115;&#x6f;&#x6e;&#64;&#103;&#x61;&#x6c;&#100;&#101;&#x72;&#x6d;&#97;&#46;&#x63;&#x6f;&#109;\" rel=\"nofollow\" shape=\"rect\">&#114;&#105;&#x63;h&#97;&#x72;&#x64;&#46;&#104;&#x61;&#x72;b&#105;&#x6e;&#x73;o&#110;&#x40;&#x67;a&#108;&#x64;&#x65;r&#109;&#x61;&#46;&#99;&#111;&#x6d;<\/a><br \/>+41 76 210 60 62<\/p>\n<p>C\u00e9line Buguet<br \/>\n<br \/>Franchises and R&amp;D Communications Director<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;t&#x6f;:&#99;&#x65;&#108;&#x69;&#110;&#x65;&#46;&#x62;u&#103;&#x75;&#101;&#x74;&#64;&#x67;a&#x6c;&#x64;&#101;&#x72;&#109;&#x61;&#46;&#x63;o&#109;\" rel=\"nofollow\" shape=\"rect\">&#x63;&#x65;&#108;&#105;n&#x65;&#x2e;&#x62;&#117;&#103;u&#x65;&#x74;&#x40;&#103;&#97;l&#x64;&#x65;&#x72;&#109;&#97;&#46;&#x63;&#x6f;&#x6d;<\/a><br \/>+41 76 249 90 87<\/p>\n<p>Emil Ivanov<br \/>\n<br \/>Head of Strategy, Investor Relations, and ESG<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;l&#x74;&#x6f;&#58;em&#x69;&#x6c;&#46;i&#x76;&#x61;&#110;&#111;v&#x40;&#x67;&#97;l&#x64;&#x65;&#114;&#109;a&#x2e;&#x63;&#111;m\" rel=\"nofollow\" shape=\"rect\">&#x65;&#x6d;&#105;l&#x2e;&#x69;&#118;&#97;n&#x6f;&#x76;&#64;&#103;a&#x6c;&#x64;&#101;rm&#x61;&#x2e;&#99;o&#x6d;<\/a><br \/>+41 21 642 78 12<\/p>\n<p>Jessica Cohen<br \/>\n<br \/>Investor Relations and Strategy Director<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#x74;&#111;:&#x6a;&#101;s&#x73;&#x69;&#99;a&#x2e;&#99;o&#x68;&#x65;&#110;&#64;&#x67;&#x61;&#108;&#x64;&#x65;&#114;m&#x61;&#x2e;&#99;o&#x6d;\" rel=\"nofollow\" shape=\"rect\">jes&#115;&#105;&#99;&#x61;&#x2e;&#x63;&#x6f;&#x68;&#x65;n&#64;g&#97;&#108;&#100;&#101;&#x72;&#x6d;&#x61;&#x2e;&#x63;&#x6f;m<\/a><br \/>+41 21 642 76 43<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Systemic Sclerosis (SSc) is a life-threatening autoimmune disease that causes severe inflammation and fibrosis, while Chronic Pruritus of Unknown Origin (CPUO) is characterized by a persistent, chronic itch with an unknown cause1-3 Nemolizumab is the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31. It is approved for &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61482","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Systemic Sclerosis (SSc) is a life-threatening autoimmune disease that causes severe inflammation and fibrosis, while Chronic Pruritus of Unknown Origin (CPUO) is characterized by a persistent, chronic itch with an unknown cause1-3 Nemolizumab is the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31. It is approved for ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-25T05:04:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250624095800\/en\/2506646\/22\/GALDERMA_LOGO_BLACK_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin\",\"datePublished\":\"2025-06-25T05:04:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\\\/\"},\"wordCount\":1478,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250624095800\\\/en\\\/2506646\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\\\/\",\"name\":\"Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250624095800\\\/en\\\/2506646\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\",\"datePublished\":\"2025-06-25T05:04:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250624095800\\\/en\\\/2506646\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250624095800\\\/en\\\/2506646\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\/","og_locale":"en_US","og_type":"article","og_title":"Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin - Pharma Trend","og_description":"Systemic Sclerosis (SSc) is a life-threatening autoimmune disease that causes severe inflammation and fibrosis, while Chronic Pruritus of Unknown Origin (CPUO) is characterized by a persistent, chronic itch with an unknown cause1-3 Nemolizumab is the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31. It is approved for ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\/","og_site_name":"Pharma Trend","article_published_time":"2025-06-25T05:04:05+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250624095800\/en\/2506646\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin","datePublished":"2025-06-25T05:04:05+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\/"},"wordCount":1478,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250624095800\/en\/2506646\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\/","url":"https:\/\/pharma-trend.com\/en\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\/","name":"Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250624095800\/en\/2506646\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","datePublished":"2025-06-25T05:04:05+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250624095800\/en\/2506646\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250624095800\/en\/2506646\/22\/GALDERMA_LOGO_BLACK_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/galderma-initiates-two-new-clinical-trials-investigating-nemolizumab-in-patients-with-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61482"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61482\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}